Moderna stock rises over 100% this year Moderna is expanding its business beyond COVID-19 vaccines using its mRNA platform. The company is moving into multivalent and seasonal respiratory markets. Moderna's investigational mRNA-based seasonal influenza vaccine, m
Moderna stock rises over 100% this year
Moderna is expanding its business beyond COVID-19 vaccines using its mRNA platform.
The company is moving into multivalent and seasonal respiratory markets.
Moderna’s investigational mRNA-based seasonal influenza vaccine, mFlusiva, has a target FDA action date of Aug. 5.
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
